New Zealand Pharmaceuticals and Healthcare Report Q4 2013:Life Sciences Market Research Reports

Life Sciences Market Research Reports

New Zealand Pharmaceuticals and Healthcare Report Q4 2013 Aug 7th 2013, 00:00, by rnrmahesh BMI View: Limited funding for New Zealand’s Pharmaceutical Management Agency (PHARMAC) will continue to be a source of discontent for innovative drugmakers. The consequential reduction in market access is also a cause for concern among patient populations. We highlight that New Zealand’s pharmaceutical market continues to rank behind Australia in terms of the attractiveness of its business environment. Headline Expenditure Forecasts ? Pharmaceuticals: NZD1.38bn (US$1.12bn) in 2012 to NZD1.42bn (US$1.06bn) in 2013; +2.9% in local currency and 1.6% in US dollar terms. ? Healthcare: NZD21.25bn (US$17.21bn) in 2012 to NZD22.08bn (US$17.67bn) in 2013; +3.9% in local currency and 2.6% in … Order / Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=110354. Complete report details with Table of Contents and more @ http://www.rnrmarketresearch.com/new-zealand-pharmaceuticals-and-healthcare-report-q4-2013-market-report.html.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions